cancer-therapy-and-biomarkers-2016_tracks-abstracts

12 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 34
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Ex vivo apoptotic, autophagic and angiogenic influence of an estradiol analogue on platelets
Lisa Repsold
University of Pretoria, South Africa
Platelets are known contributors to vascularization, metastasis and growth of tumors. Upon their interaction with cancer cells
they are activated resulting in the release of angiogenic activators thereby promoting angiogenesis. Angiogenesis-regulating
proteins are ideal biomarkers in the study of cancer pathophysiology and represent desirable therapeutic- and diagnostic tar-
gets.
The in silico-designed analogue of 2-methoxyestradiol, namely 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16),
binds to carbonic anhydrase II delaying early metabolism and is thus carried into the circulation. The effect it potentiates on
blood components, especially on platelets, is of significance in cancer progression. This study thus investigated the possible ex
vivo apoptotic, autophagic and angiogenic effects of ESE-16 on platelets.
Scanning electron microscopy was used to assess morphological changes in platelets after exposure to ESE-16 and no changes
were observed in ESE-16-treated platelets. The possible induction of apoptosis and autophagy was determined by annexin
V-FITC, measurement of caspase 3 activity, autophagy-related protein 5 levels, light chain 3-I to light chain 3-II conversion
and monodansylcadaverine staining which indicated that there was no increase in apoptosis or autophagy when platelets
were exposed to ESE-16. The expression of the angiogenic proteins namely vascular endothelial growth factor, platelet derived
growth factor and matrix metallopeptidase-9 was also assessed and results showed that levels were significantly increased after
platelets were added to MCF-7 cells.
This is the first ex vivo study to highlight possible involvement of angiogenesis, apoptosis, autophagy in platelets after exposure
to this potential anti-cancer compound warranting further investigation concerning these signaling pathway targets on plate-
lets of cancer patients.
Biography
Lisa Repsold is a PhD student at the Department of Physiology, University of Pretoria, South Africa. She completed her Masters degree cum laude and is currently
conducting her PhD study with a title: ‘Angiogenic, apoptotic and autophagic profiling of chronic myeloid leukaemia patients’ platelets ex vivo before and after
treatment with Imatinib’. She has published three papers in internationally accredited peer-reviewed journals and presented her research at national conferences.
In her research career she has mastered several scientific techniques including scanning and transmission electron microscopy, flow cytometry, cell culture
techniques and western blot.
Lisa Repsold, Oncol Cancer Case Rep 2016,2:3(Suppl)